Its very bad news - best case - its horrible news worst case. You can't sugar coat it. Take off your rose color glasses and stop talking your book and start acting impartial.
I dont care if IDIX goes to $10 or $0.10 --> but based on theis news there's no way to paint a rosey picture. It's got a fairly large fully dilluted market cap as well and everything else they have is preclinical.
I may not know IDIX history - but as soon as I saw this news if I were a shareholer or a fund manager - I would have gotten rid of IDIX. I know you will hold it to $0 because you like their science but NVS not wanting to partner IDX184 casts HUGE DOUBT on their only drug in clinical development. Fully dilluted market cap close to $180m implies a lot of value to a drug which NVS just implied has little value (atleast to them)
Market Data 
Markets 
AI
